Rocket Lab (RKLB) shares, trading near $53 after a 15% rally on November 6 ahead of Q3 results, reflect trader focus on sustained revenue momentum versus execution risks. The company has posted record quarterly sales each period in 2026, including $234 million in Q2 with a $2.36 billion backlog, while guiding Q3 revenue of $250–265 million. However, the Neutron rocket’s first launch slipped to 2027 due to carbon-fiber component issues, widening adjusted EBITDA losses are expected, and the stock remains down roughly 65% from its May peak near $150 amid a high price-to-sales multiple above 30x. Analysts maintain a Moderate Buy consensus with average targets near $102, citing Electron launch cadence, the pending Iridium acquisition, and space-systems growth, though near-term volatility hinges on the November 9 earnings release and any updated guidance on cash burn or launch timelines.